Drug Type Small molecule drug |
Synonyms Molixan, BAM-205, NOV-205 |
Target |
Action stimulants |
Mechanism NGFB stimulants(Beta-nerve growth factor stimulants) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date Russia (10 Sep 2006), |
Regulation- |
Molecular FormulaC10H17N3O6S |
InChIKeyRWSXRVCMGQZWBV-WDSKDSINSA-N |
CAS Registry70-18-8 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Hepatitis B | Russia | 27 Oct 2006 | |
Hepatitis C | Russia | 10 Sep 2006 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
COVID-19 | Phase 3 | Russia | 06 Mar 2021 | |
Hepatitis C, Chronic | Phase 2 | United States | 01 Mar 2010 | |
Chronic hepatitis C genotype 1 | Phase 1 | - | 01 Aug 2006 | |
Radiation Injuries | Preclinical | United States | - |